• Worked as a Senior Researcher at Hanmi Pharm (PL for HM95573 (Licensed out to Genentech))
  • PhD, Sogang University

Son Jung Beom, PhD / CTO, Voronoi Bio

While working at Hanmi Pharm, Mr. Sohn led the project of developing an RAF inhibitor, later licensed out to Genentech.

 “Generally, the compounds containing carbon are called organic compounds. Humans, also as an organism, has protected or cured his/her body using animals and plants found in nature.
As science advances, pharmacologically active substances could be separated from the nature, but many limitations exist for them to be used widely on people. For this reason, people needed synthetic compounds with pharmacologically active substances, and now they rely on organic chemistry to establish such goal.
Based on this knowledge, Voronoi Bio focuses on discovering novel small molecule kinase inhibitors, which regulate the transduction of signal kinase pathway for oncology inflammation and neurodegenerative disease.
However, developing new drugs based on simple organic chemistry knowledge costs substantial time and money. To overcome that hurdle, Voronoi Bio established the best hit discovery system in Korea using in silico methodologies. Through close collaboration with the molecular modeling team, we are structuring novel kinase inhibitors, analyzing the correlation between structure and activity, to expedite drug development.
As a result, we have discovered numerous new core structures that are patentable, and with further derivative synthesis to those chemical cores, we have also secured countless therapeutic compounds. In addition, we synchronized an in-house ADME team to review pharmacological nature, which can accelerate candidate discovery. We will do our best to shorten the lead time for new drug development, by working closely with internal and external partners.”

  • Worked as a Senior Researcher at Hanmi Pharm (PL for HM95573 (Licensed out to Genentech))
  • PhD, Sogang University

Son Jung Beom, PhD / CTO, Voronoi Bio

While working at Hanmi Pharm, Mr. Sohn led the project of developing an RAF inhibitor, later licensed out to Genentech.

 “Generally, the compounds containing carbon are called organic compounds. Humans, also as an organism, has protected or cured his/her body using animals and plants found in nature.
As science advances, pharmacologically active substances could be separated from the nature, but many limitations exist for them to be used widely on people. For this reason, people needed synthetic compounds with pharmacologically active substances, and now they rely on organic chemistry to establish such goal.
Based on this knowledge, Voronoi Bio focuses on discovering novel small molecule kinase inhibitors, which regulate the transduction of signal kinase pathway for oncology inflammation and neurodegenerative disease.
However, developing new drugs based on simple organic chemistry knowledge costs substantial time and money. To overcome that hurdle, Voronoi Bio established the best hit discovery system in Korea using in silico methodologies. Through close collaboration with the molecular modeling team, we are structuring novel kinase inhibitors, analyzing the correlation between structure and activity, to expedite drug development.
As a result, we have discovered numerous new core structures that are patentable, and with further derivative synthesis to those chemical cores, we have also secured countless therapeutic compounds. In addition, we synchronized an in-house ADME team to review pharmacological nature, which can accelerate candidate discovery. We will do our best to shorten the lead time for new drug development, by working closely with internal and external partners.”